EPAS1 and metabolic dysfunction-associated steatotic liver disease: Early studies, looking for example at the effect of HIF2α antagonism in HFD induced hepatosteatosis in mice have shown promising results (9), but studies in more severe models of NAFLD and NASH do still need be conducted.